

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International BureauDate AB  
F-1403

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup>:</b> C07K 13/00, 9/00, C12Q 1/00 A61K 39/00, C07H 15/12	<b>A1</b>	<b>(11) International Publication Number:</b> WO 90/13573 <b>(43) International Publication Date:</b> 15 November 1990 (15.11.90)
<b>(21) International Application Number:</b> PCT/US90/02338 <b>(22) International Filing Date:</b> 30 April 1990 (30.04.90)  <b>(30) Priority data:</b> 348,784 8 May 1989 (08.05.89) US 447,810 8 December 1989 (08.12.89) US  <b>(71) Applicant:</b> IDEXX CORPORATION [US/US]; 100 Fore Street, Portland, ME 04101 (US).  <b>(72) Inventors:</b> ANDERSON, Philip, R., Andersen ; 81 Bramblewood Drive, Portland, ME 04103 (US). O'CONNOR, Thomas, P. ; 52 Summit Circle, Westbrook, ME 04092 (US). TONELLI, Quentin, J. ; 37 Wellington Road, Portland, ME 04103 (US).		<b>(74) Agent:</b> FREEMAN, John, W.; Fish & Richardson, One Financial Center, Suite 2500, Boston, MA 02111-2658 (US).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>FOR YOUR PATENT NEEDS</b> AML Information Services P.O. Box 415 Corte Madera, CA 94925 415-927-0340
<b>(54) Title:</b> POLYPEPTIDES OF FELINE T-CELL LYMPHOTROPIC LENTIVIRUS		
<b>(57) Abstract</b>		
<p>In a first aspect, the invention features a purified polypeptide having an epitope of an antigenic polypeptide of FIV. The polypeptide may be glycosylated or unglycosylated. By antigenic polypeptide is meant a polypeptide which is able to raise (with the aid of an adjuvant if necessary) an antibody response in cats. The polypeptide may be a polypeptide fragment of at least 5 amino acids, or a polypeptide naturally occurring in FIV particles. The fragment may be obtained from a naturally-occurring polypeptide, for example, by enzymatic digestion of a naturally occurring polypeptide, or may be produced by isolation or synthesis of a gene encoding a desired polypeptide and expression of that polypeptide within a desired expression system, for example, a bacterial, yeast, or mammalian expression system.</p>		

BEST AVAILABLE COPY

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT:

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

POLYPEPTIDES OF FELINE  
T-CELL LYMPHOTROPIC LENTIVIRUS

Background of the Invention

This application is a continuation-in-part of O'Connor et al., Application Serial No. 348,784 filed 1989 entitled Polypeptides of Feline T-Cell Lymphotropic Lentivirus which is a continuation-in-part of O'Connor et al., Application Serial No. 293,906, filed January 5, 1989, entitled "Monoclonal Antibodies to Feline-T-Lymphotropic Lentivirus", which is a continuation-in-part of O'Connor et al., Application Serial No. 279,989, filed December 5, 1988, entitled "Monoclonal Antibodies to Feline-T-Lymphotropic Lentivirus", the whole of which (including drawings) are hereby incorporated by reference herein.

This invention relates to purification of polypeptides from feline T-cell lymphotropic lentivirus (FIV).

FIV is a retrovirus originally isolated from cats which exhibit an AIDS-like syndrome. Pederson et al., 235 Science 790, 1987. The virus belongs to the same group as the human immunodeficiency virus (HIV), the causative agent of human AIDS. Pederson et al., describe detection of antibody to FIV by an immunofluorescent assay, and by Western blots, using virus purified by centrifugation on sucrose gradients in Tris base, pH 7.4, containing 0.1M NaCl and 1mM EDTA. A few protein bands were detected and, although antigenic comparison was not made, the positions of these bands were tentatively said to correspond to the major core protein, p24 the gag precursor protein, p55, and the

2

endonuclease protein, p32, of HIV.

Pederson et al., U.S. Patent Application Filed August 26, 1987 entitled "Feline T-Lymphotropic Lentivirus" (which is not admitted to be prior art to the present application) describes the results presented by Pederson et al., supra, and states that Western blotting of FIV infected cell lysates yielded major protein bands at approximately 22-26 kD, usually about 24 kD; 50-60 kD, usually about 55 kD; and 28-36 kD, usually about 32 kD.

Summary of the Invention

In a first aspect, the invention features a purified polypeptide having an epitope of an antigenic polypeptide of FIV. The polypeptide may be glycosylated or unglycosylated. By antigenic polypeptide is meant a polypeptide which is able to raise (with the aid of an adjuvant if necessary) an antibody response in cats. The polypeptide may be a polypeptide fragment of at least 5 amino acids, or a polypeptide naturally occurring in FIV particles. The fragment may be obtained from a naturally-occurring polypeptide, for example, by enzymatic digestion of a naturally occurring polypeptide, or may be produced by isolation or synthesis of a gene encoding a desired polypeptide and expression of that polypeptide within a desired expression system, for example, a bacterial, yeast, or mammalian expression system.

By epitope is meant a single antigenic site of an antigenic polypeptide. Such an epitope is recognized specifically by a monoclonal antibody to an antigenic polypeptide of FIV.

By purified is meant that the polypeptide is separated from other cell components with which it naturally occurs, for example, FIV polypeptides.

Preferably, the polypeptide is sufficiently pure to permit its use to prepare a monoclonal antibody to the polypeptide, and even more preferably, pure enough to allow the amino acid sequence of the polypeptide to be determined by standard procedure. Generally, the purified polypeptide is biologically active in that it is suitable for preparation of a monoclonal antibody, or is suitable for detection of naturally-occurring antibodies within the serum of a cat.

In preferred embodiments, the purified polypeptide has at least 75% amino acid homology to a polypeptide fragment of at least 20 amino acids obtained from an FIV gag or env polypeptide, most preferably the purified polypeptide includes an amino acid sequence having at least 75% homology to a whole of a gag or env polypeptide, even more preferably, the purified polypeptide is an entire gag or env amino acid sequence. Examples of gag and env polypeptides include p10, p15, p26, gp40, gp100, and gp130.

In a second aspect, the invention features a method for detecting an antibody to FIV within a sample, including the steps of providing a purified polypeptide as described above, and contacting that polypeptide under conditions suitable to allow an antibody/polypeptide complex to form between antibodies within the sample and the purified polypeptide, and detecting the formation of such complexes. The presence of antibody/polypeptide complexes is indicative of antibody to FIV present within the sample.

In a third aspect, the invention features a purified nucleic acid including a 50 nucleotide sequence having at least 90% homology with a 50 nucleotide sequence naturally occurring in an FIV particle. By purified is meant that the nucleic acid is substantially

4

separated away from all of the components with which it naturally occurs, e.g., polypeptides and other nucleic acids. Preferably, the nucleic acid is completely separated from such components, and is a pure solution of nucleic acid, or is held within a cell in which it does not naturally occur, e.g., a bacterial cell, another viral particle or a non-feline eucaryotic cell. By 90% homology is meant that the nucleotide sequence is identical at at least 45 of the 50 nucleotides.

In preferred embodiments, the nucleic acid encodes a polypeptide including an epitope of an antigenic polypeptide of FIV, e.g., an epitope of a gag or env polypeptide of FIV. Most preferably the nucleic acid is carried in an expression vector and can be expressed in a bacterial, fungal or other eucaryotic cell, e.g., a mammalian cell.

In a related aspect the invention features purified polypeptide including ten or more contiguous amino acids taken from the sequence (using standard letters to represent amino acids)

V-Q-S-R-G-S-G-F-V-C-F-N-C-K-K-P-G-H-L-A-R-Q-S-H or  
P-I-Q-T-V-N-G-V-P-Q-Y-V-A-L-D-P-K-M-V-S or  
S-V-Q-S-R-G-Q-G-P-V-A-F-N.

Applicants have provided polypeptides suitable for specific detection of FIV antibodies and thus have allowed accurate detection of infection with FIV. Applicants have also provided polypeptides useful for production of vaccines to prevent disease caused by FIV in cats.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiment thereof, and from the claims.

5

### Description of the Preferred Embodiments

The drawings will first briefly be described.

#### Drawings

Fig. 1 is a photograph of the major viral associated proteins of FIV identified by polyacrylamide gel electrophoresis (PAGE) and stained with Commassie Blue R250 (lane A); molecular weight standards are shown in lane B;

Fig. 2 is a photograph of a Western immunoblot analysis of antibodies to FIV found in serum from cats identified as positive by an ELISA assay for FIV antibodies;

Fig. 3 is a graphical representation of elution of FIV polypeptides during HPLC purification;

Fig. 4 is a photograph of an SDS-polyacrylamide gel after electrophoresis and staining with silver, showing purity of various FIV polypeptides; and

Fig. 5 is the nucleic acid sequence, and corresponding amino acid sequence, of various portions of cloned FIV nucleic acid.

#### Antigenic FIV Polypeptides

FIV polypeptide antigens useful in this invention are generally described above. Polypeptides useful in this invention may be purified from virus isolated as described below and fragments of the purified polypeptides isolated by enzymatic treatment or other standard procedures. Further, the polypeptides may be synthesized by standard in vitro expression systems in which DNA encoding for the FIV polypeptide is cloned and expressed in a bacterial, yeast, or mammalian cell expression system. Such DNA may be isolated and expressed as described below. The polypeptides may also be synthesized by standard chemical methods, for example, the polypeptide segments of various FIV

6

polypeptides given below can be synthesized.. In the following example FIV polypeptides were obtained directly from FIV-infected cells and took the form of polypeptides naturally occurring in an FIV virus particle. This example is not limiting to the present invention, and those skilled in the art will recognize the many alternative methods for obtaining polypeptides of this invention. The polypeptides are referred to according to molecular weight, thus a polypeptide of 30kD is termed p30, and a glycoprotein of this weight is termed gp30.

Master seed virus producing cultures were obtained in the form of a continuous feline cell line infected with FIV isolate #2427 (CRFK-FIV or Petaluma strain) from Dr. Neils Pederson (University of California, Davis, California). The parent cell line is Crandell feline kidney cell persistently infected with FIV. The cell line was deposited with the American Type Culture Collection on July 13, 1988 and assigned the number CRL9761. Applicants and their assignees acknowledge their responsibility to replace this culture should it die before the end of the term of a patent issued hereon, 5 years after the last request for a culture, or 30 years, whichever is the longer, and its responsibility to notify the depository of the issuance of such a patent, at which time the deposit will be made irrevocably available to the public. Until that time the deposit will be made available to the Commissioner of Patents under the terms of 37 C.F.R. §1-14 and 35 U.S.C. §112.

Other virus cultures can be obtained as described by both Pederson et al. references, supra, or by Harbour et al., 122 The Veterinary Record 84, 1988. Seed stocks of virus producing cell cultures were

7

obtained by freeze-downs of FIV-infected master seed cell cultures following at least 19 post infection passages in culture. Additional seed stocks of virus producing cultures were obtained by either infection of the continuous feline cell culture with FIV master seed virus or by single cell microwell cloning of high level FIV producers from the original FIV infected master seed cell culture. For propagation, master seed virus infected feline cell cultures were inoculated into tissue cell culture flasks. Following growth to a confluent monolayer of cells, tissue culture fluid was harvested at intervals of 2-5 days.

Working seed virus was produced by propagation by the master seed cell line permanently infected with FIV. An inoculum was added to tissue culture flasks, in Dulbecco's Modified Eagles medium containing 2 mM L-glutamine and 4.5 g per liter/glucose (DMEM) containing 100 units per ml. penicillin and streptomycin and 2 mM glutamine. An inoculum was added to tissue culture flasks, incubated, and the spent tissue culture fluid harvested when the cells were grown to confluence. The cells were released from the culture vessel with trypsin/EDTA and diluted between 1:5 and 1:25 (typically 1:8) in medium. Typically the flasks were incubated at 36°C-38°C for a maximum of 7 days (between 3 and 7 days) before fluid and cell harvest. The harvested fluid, including cell material, was centrifuged in a high speed centrifuge (Sorval RC-5B or Beckman J2-21) leading to separation of supernatant and cell pellet material. The cell pellet was discarded, and the supernatant culture fluid used to prepare working virus. The clarified supernatant was made 0.5 M in NaCl and 4%-10% (usually 7%) in polyethylene glycol (PEG 8000, Sigma). Following overnight incubation at 2°C-7°C, virus was pelleted (at

8

13,000 x g for 30 min.) and resuspended in buffer (10 mM Tris, pH 7.6 300 mM NaCl, 1mM EDTA, at 2°C-7°C). After overnight incubation the virus was centrifuged at 13,000 x g for 15 min., the pellet discarded and the  
5 supernatant centrifuged on a 50%/80% discontinuous glycerol step gradient in 10 mM Tris 300 mM NaCl, 1 mM EDTA at pH 7.6. Centrifugation was at 100,000 x g for 3 hrs. at 4°C and the FIV viral band at the 50%-80% interface collected. The band was suspended in 10 mM  
10 Tris, 0.3 M NaCl and 1 mM EDTA and diluted 1:3 in the buffer and repelleted at 100,000 x g for 1 hr. The resulting pellet was purified virus and was resuspended in the above buffer and stored at -70°C. The resulting virus was substantially free from FIV host cell proteins and was composed of at least 5% p26 (the major  
15 nucleocapsid protein, as measured by densitometric scans of Commassie Blue 250 stained SDS/PAGE as total protein).

Such purified virus may be obtained by other  
20 techniques, however, applicants have found that high molecular weight contaminants present in virus preparations may be eliminated by use of the high salt (i.e., greater than physiological range salt concentration) used in the gradient centrifugation  
25 procedure.

Referring to Fig. 1, polypeptides associated with purified FIV were analyzed by SDS/PAGE and compared with polypeptides isolated in an identical manner from the spent culture medium of uninfected cells. Analysis  
30 of the Commassie Blue stained gels revealed three major polypeptides with molecular weights of about 10, 15, and 26 kD, named p10, p15 and p26, respectively.

When an ELISA test was performed using disrupted FIV to identify cats possessing polyclonal

9

antibody to FIV polypeptides, and Western blot analysis then performed on feline sera determined to be positive by ELISA, each of the cats had antibodies which reacted with one or more polypeptides of molecular weight p10, 15, 26, 40 and 65 kD under the conditions used.

Referring to Fig. 2, a standard Western immuno blot was performed as described by Towbin et al., 76 Proc. Natl. Acad. Sci USA 4350, 1979. Briefly, FIV was disrupted with SDS and proteins transferred to a sheet of nitrocellulose. The nitrocellulose sheet was blocked with 30% calf serum, 1% bovine serum albumin (BSA), and 0.05% Tween 20 in Dulbecco's phosphate buffer saline. The sheets were cut into 0.5 cm strips and incubated with a 1:100 dilution of serum sample in blocking buffer for 2 hrs. for 20-22°C. Strips were repeatedly washed with washing buffer (0.05% Tween 20 in Dulbecco's phosphate buffer saline) and then incubated with a second antibody (specific for feline heavy and light chain Ig) horseradish peroxidase conjugate (obtained from Kirkguard and Perry Laboratories Inc. Gaithersburg, MD). After 1 hr. incubation, the strips were repeatedly washed with washing buffer and incubated with the precipitating substrate 4-chloronaphthol for 10 min. The strips were partially dried and the results interpreted immediately. The serum in each of the lanes A-G was obtained from various cats infected with FIV. Predominant cross-reactivity is detected with p26 and p15 and to a lesser extent with p10. Other proteins of 32, 40, 47 and 65 kD molecular weight are also detected.

Certain viral polypeptides, such as the gag (e.g., p26) antigenic polypeptides, are abundant in purified viral preparations, others such as the viral envelope polypeptides (e.g., gp130) tend to be lost

during viral purification, and electrotransfer less efficiently for Western blot analysis than the gag antigens. Therefore, in order to more readily detect the viral envelope (env) and the gag precursor polypeptides, FIV cell extracts were labeled with <sup>35</sup>S-methionine and cysteine and examined by immunoprecipitation (RIPA). Confluent cultures of cells infected with FIV were incubated for 30 min. in methionine and cysteine-free Dulbecco's modified Eagle's medium. The cell cultures were then incubated for 4 hrs. in 8 ml of the same medium containing 100 microCuries per ml of <sup>35</sup>S-methionine and <sup>35</sup>S-cysteine (specific activity 1200 Curies per mM, New England Nuclear Corporation, Boston, MA). The radioactive tissue culture fluids were removed and the cells lysed with 5 ml of 10 mM sodium phosphate buffer pH 7.5 containing 100 mM NaCl, 1% Triton X 100, 0.5% sodium deoxycholate, 0.1% SDS, 0.1mM phenylmethylsulfonylfluoride, and 100 Kallikrein inactivator units of aprotinin per ml. (Sigma Chemical Co., St. Louis, MO). Before use, the cell lysates were clarified by centrifugation 100,000 x g for 30 min. and the pellet discarded. Aliquots of the labelled cell lysates (0.1 ml) and 5 µl of serum being tested were mixed in a microcentrifuge tube and incubated for 1 hr. at 37°C and then overnight at 4°C. The next day, 0.2 ml of a 5% suspension of protein A Sepharose CL-4B beads (Pharmacia, Piscataway, NJ) in 10 mM of phosphate buffer, pH 7.5 containing 100 mM NaCl, 1% Triton X-100 and 0.1% SDS was added to each tube and mixed for 30 min. at 4°C. The antibody/antigen complexes bound to the protein A Sepharose beads were collected by centrifugation (2 min. at 20,000 x g) and washed 3 times in lysing buffer. The final pellet was resuspended in

(1)

25  $\mu$ l SDS/PAGE loading buffer and heated and 100°C for 3 minutes. The Sepharose beads were removed by centrifugation and the supernatant applied to a PAGE. Gels were processed for fluorography using enlightening<sup>TM</sup> (New England Nuclear Corporation, Boston, MA) and exposed at -70° to Kodak XR-5 film. Sera from experimentally infected cats recognize polypeptides of 15, 22, 36, 40, 47, 110 and 130 kD. Although there were some quantitative and qualitative differences all cats appear to mount a response to p22, gp40, gp47 and gp130.

In order to determine which of the polypeptides identified by RIPA-PAGE analysis were related to the major internal structural protein, p26, RIPA-PAGE analysis was carried out using monoclonal antibodies which reacted with p26 as determined by Western blotting. This monoclonal immunoprecipitated proteins p47, p36, p22 and p15. High molecular weight polypeptides (130 kD) of FIV which were not detected by the p26 specific monoclonal antibody, were identified by RIPA-PAGE. A protein of molecular weight 100 kD was also detectable utilizing serum antibodies obtained from some infected cats.

In another example, antigenic glycopeptides of FIV can be obtained as follows. Actively growing CRFK FTLV infected cells were scraped from roller bottles, gently washed with phosphate-buffered saline (PBS), and pelleted. The cell pellet was gently resuspended in 10 mM sodium phosphate, pH 7.2, at a ratio of 1 ml buffer to 0.1 ml of cell pellet. This suspension was incubated on ice or refrigerated for 5-10 min., vigorously vortex mixed for 30 seconds, and four volumes of PBS with 1mM PMSF added. The mixture was then vigorously homogenized for 90-120 seconds with a Brinkmann Homogenizer PT10/35

62

with a PTA 20 generator.

The resulting homogenate was clarified for 20 minutes at 5,000 x g. The supernatant fraction was discarded and the cell membrane pellet resuspended in PBS + 0.2% Triton X-100 at a ratio of 2.5 ml buffer to 0.1 ml original cell pellet. The mixture was then vigorously homogenized for 90-120 seconds with a Brinkmann Homogenizer PT 10/35 with a PTA 20 generator. The resulting homogenate was clarified at 100,000 x g for 1 hr, the supernatant decanted off and batch bound overnight at 20-23°C on Pharmacia Lentil Lectin Sepharose 4B at a ratio of 6 ml of resin to 5 ml of original cell pellet.

The Lentil Lectin Suspension was poured through a column, the resin collected, and washed with 15 column volumes of PBS - 0.2% Triton X-100. The glycoproteins were then eluted from the resin by subjecting the resin to 5-10 column volumes of PBS + 0.2% Triton X-100 - 200 mM methyl  $\alpha$ -D mannopyranoside, collecting fractions of 1 column volume/tube.

The isolation of glycoproteins was verified by 9% SDS-PAGE electrophoresis, and checked using  $^{35}$ S-radiolabeled cell preparations in conjunction with RIPA data.

Further purification of viral glycoprotein from host cell glycoprotein includes use of HPLC, or of a polyclonal or monoclonal antibody for affinity chromatography.

#### Example 1: $\alpha$ Gal Polypeptide Purification

Isolated virus (250-500 microliters) was combined with two volumes of 6M guanidine hydrochloride, pH 3 (adjusted with 20% trifluoroacetic acid in water). The mixture was vortexed and incubated at 37°C-40°C in a water bath for 20-25 minutes. The

/3

incubated solution was filtered through a pre-wetted (100 microliters of 6M guanidine hydrochloride, pH 3) 0.45 micron gel aquadisk filter (No. 4184) and the filter rinsed with 100 microliters of 6M guanidine hydrochloride pH 3. The filtered sample was loaded onto an HPLC column for purification.

The HPLC system consisted of a Beckman HPLC having three 110V pumps, a 421 controller, a 166 variable wavelength detector, a 427 integrator, a 210A injector with dynamic mixer, and a 1000 microliter sample. The column was a Waters radial compression cartridge held in an RCM-100 column holder with a modified inlet connector (Waters MicroBond-A-Pak Fenile 10 MU 8 mm x 10 cm cartridge No. 85722 with a guard pak resolve CN cartridge, No. 85826). The system was set such that two levers were compressed and the pressure was in the mid-yellow zone.

Purification was by a multi-step gradient from aqueous 0.1% trifluoroacetic acid (v/v solvent A) to aceto nitrol containing 0.1% trifluoroacetic acid (v/v, solvent B).

Fractions were collected and condensed by a Savant Speed Vac to remove all solvents to a final volume ranging from 50-100 microliters. The condensed fractions were neutralized by addition of 200-300 microliters of 50 mM or 100 mM sodium phosphate buffer, pH 7.2. The buffered fraction pHs were then checked with pH paper and, if the pH was still below 6, 1N NaOH added until the pH was brought within the range of 6.5-7.5. The neutralized fractions were frozen at -20°C until use.

Referring to Fig. 3, the printout from an HPLC column described above is shown. The flow rate was at 1 ml per minute starting with 100% of solvent A. After 15

14

min. the solvent was changed to contain 26% solvent B, 10 min. later to 31% solvent B, 12 min. later to 37.5% solvent B, 5 min. later to 40% solvent B, 6 min. later to 43% solvent B, 8 min. later to 45% solvent B, 15 min. later to 60% solvent, and 20 min. later to 100% solvent B. Peaks corresponding to p10, p15, and p26 are indicated in Fig. 3. Fractions containing these peaks were collected.

Referring to Fig. 4, fractions corresponding to p10, p15 and p26 were run in an SDS-polyacrylamide gel containing 15% bis-acrylamide at 70V. The gel was stained with silver using a Biorad Silver Staining Kit 161-0443. The isolated fractions corresponding to p15, p10, and p26 were essentially homogeneous solutions of the FIV polypeptides.

The isolated FIV polypeptides were analyzed by standard technique for their amino acid sequence, yielding the following results (? indicates uncertainty in the actual amino acid, or no knowledge at all).

p26

Number 1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20

Amino

Acid P-I-Q-T-V-N-G-V-P-Q-Y-V-A-L-D-F-K-M-V-S

p10

Number 1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-

Amino

Acid V-Q-S-R-G-S-G-P-V-C-F-N-C-K-K-P-G-H-L-

Number 20-21-22-23-24

Amino

Acid A-R-Q-S-H

p15

Number 0-1-2-3-4-5-6-7-8-9-10-11-12-13

Amino

Acid S-V-Q-S-R-G-Q-G-P-V-A-F-N-?

15

In order to determine if the purified polypeptide is useful in this invention, that is, whether the polypeptide is antigenic, any standard procedure can be used. For example an ELISA test can be performed using a polyclonal antibody from cat serum to determine whether the polypeptide is cross-reactive. Alternatively, the polypeptide can be injected with or without an adjuvant, into an animal, e.g., a mouse, to determine if it causes antibodies to be raised to it. These polypeptides are useful for production of vaccines to prevent FIV-caused disease symptoms and FIV infection in cats. These vaccines are produced by standard procedure. Preferably the gag or env polypeptides are provided in a standard inoculation medium and injected intravenously, intrarterially or otherwise into a cat at a level of 1-100 ug/kg animal at intervals of 3-4 weeks until immunity to FIV is produced.

#### FIV Monoclonal Antibodies

Antibodies to FIV polypeptides are useful aids for identification of a purified polypeptide (as described above), and for purifying polypeptides. They are also useful to determine the antigenicity of any polypeptide. An example of preparation of useful antibodies follows. These antibodies are monoclonal antibodies which allow specific detection and purification of either individual or a small number of FIV polypeptides.

Balb/CJ (Jackson Labs) mice were immunized with an initial injection of 50 micrograms of FIV virus (prepared as described above) per mouse mixed 1:1 with Difco Bacto adjuvant complete. After two weeks a booster injection of 100 micrograms of FIV virus was injected into each mouse intravenously without adjuvant. Three days after the booster injection a

16

fusion was performed with mouse myeloma cell lines FO or p3X63-Ag8.653. Mid log phase myeloma lines were harvested on the day of fusion and checked for viability. The cells were spun at 300 x g for 8 min., separated from the growth medium, and resuspended in serum free DME.

For fusion, an FIV-inoculated mouse was killed by cervical dislocation and the spleen aseptically removed. The spleen was washed three times in serum free DME and placed in a sterile Petri dish containing 20 ml of complete medium (DME containing 20% bovine fetal serum, 100 units per ml. of penicillin and streptomycin, and 1 mM sodium pyruvate). To release cells, the spleen was perfused with a 23 gauge needle.

Cells were placed in a 50 ml conical centrifuge tube and pelleted at 300 x g for 8 min. The pellet resuspended in 5 ml of 0.17M ammonium chloride and placed on ice for 8 min. 5 ml of bovine fetal serum (20%) was added and the cells pelleted again at 300 x g for 8 min. After resuspension in 10 ml DME the cells were counted and the spleen and myeloma cells mixed in a ratio of 3:1. The cell mixture was pelleted at 200 x g for 10 minutes, the supernatant decanted, and the pellet allowed to stand for 5 min. Over a period of 1 min., 1 ml of 50% PEG (PEG 1500 mixed 1:1 with Hepes pH 8.1) at 37°C was added. After 1 min. incubation at 37°C, 1 ml of DME was added over a period of another 1 min. and then a second 1 ml of serum free medium added over a period of 1 min. Finally, 10 ml of DME was added over a period of 2 min., the cells pelleted at 200 x g for 8 min., and the pellet resuspended in complete medium containing 0.016 mM thymidine, 0.1 mM hypoxanthine, 0.5 micromolar aminopterin, and 10% hybridoma cloning factor (1 x HAT). The cells were plated into 96-well plates.

17

After 3, 5 and 7 days half of the medium in the fusion plates was removed and replaced with fresh 1 x HAT. After 11 days the hybridoma cell supernatant was screened by an ELISA test. In this test, 96 well plates were coated with FIV virus by standard technique. One hundred microliters of supernatant from each well was added to a corresponding well on a screening plate and incubated for 1 hr. at 20-22°C. After incubation, each well was washed three times with distilled water and 100 microliters of a horseradish peroxidase conjugate of goat anti-mouse IgG (H + L), A, M (1:1500 dilution) was added to each well and incubated for 1 hr. at 20-22°C. After three washes with distilled water, the substrate OPD/hydrogen peroxide was added and incubation continued for five to fifteen minutes. One hundred microliters of a stop solution (1 M hydrochloric acid) was then added and the absorbance at 490 nm read. Cultures which had an optical density reading greater than the control wells were removed to 2 cm<sup>2</sup> culture dishes, with the addition of normal mouse spleen cells in 1 x HT medium. After a further three days all of the 2 cm<sup>2</sup> cultures were rescreened for antibody and those testing positive again were cloned by limiting dilution. The cells in each 2 cm<sup>2</sup> culture were counted and cell concentration adjusted to 1 x 10<sup>5</sup> cells per ml. The cells were diluted in complete medium and normal mouse spleen cells at concentrations of hybridoma cells of 5, 10 and 50 cells per ml added. The cells were plated into 96-well plates for each dilution. After 10 days the cloning plates were screened for growth. About 37% of all wells showed growth. The growth-positive wells were screened for antibody and those testing positive expanded to 2 cm<sup>2</sup> cultures and provided with normal mouse spleen cells. The cloning procedure was repeated 2 times until

18  
a stable antibody-producing hybridoma was obtained. At this point the cell culture was expanded from 2 to 9 to 75 to 150 cm<sup>2</sup> culture vessels, at which point ascite production could be commenced.

5 For ascites production, pristane primed IRCF1 female mice were used. 0.5 ml of pristane was injected intraperitoneally (IP) to each mouse, and the mouse allowed to rest for 10-60 days. At this time  $4.5 \times 10^6$  cells were injected IP into each mouse and ascites  
10 formed in 7-14 days. Ascites fluid was harvested with a pasteur pipette through a hole in the peritoneum.

Antibodies to glycoproteins can also be isolated and detected. In particular, antibodies to two glycoproteins of molecular weight 40 kD (gp40) and 130  
15 kD (gp130) which are detected using PAGE and RIPA respectively.

Monoclonals useful in this invention for purification and identification of specific polypeptides of FIV include those which are specific for FIV and form  
20 a sufficiently strong interaction with an FIV epitope, and an FIV antigen, to be useful in an immunoassay, for example, an ELISA, to detect an FIV antigen. In order to determine which of the above monoclonal antibodies are useful in this invention one main test was used.  
25 This entailed determination of whether the monoclonal antibody can bind FIV antigen and be detected with a conjugate of polyclonal antibody to FIV (an ELISA test, described above).

30 Another test is to perform a Western blot to determine whether the monoclonal antibody has good reactivity with one or more FIV antigens. Generally, those monoclonals which show poor reactivity, that is, produce faint bands on the Western blot, are not suitable in this invention. Yet another test involves

19

radioimmunoprecipitation assay (RIPA) where FIV virus labeled with  $^{35}\text{S}$ -methionine is reacted with a monoclonal antibody to form within immunoprecipitate, and the immunoprecipitate run in a SDS-PAGE and autoradiographed to detect the labelled proteins. This analysis determines which of the monoclonal antibodies is able to detect precursor FIV antigenic polypeptides and not just mature polypeptides.

#### Antibody Detection

The above antigenic polypeptides can be used to detect naturally occurring antibodies produced by cats. Such detection can be any standard immunoassay procedure, for example, by an ELISA test, as described above. One example of such a test follows. This example is not limiting to the present invention and those skilled in the art will recognize that any of many other standard procedures can be used.

#### Example 2: Antibody assay

Materials required to perform this assay include 96 well flat bottom microtiter strips coated with a solution containing the appropriate test antigen (e.g., p26, p15, or p10). The test wells were coated with 100 $\mu\text{l}$  of a solution containing 0.15 micrograms antigen in 0.25 molar sodium citrate, pH 7.5. The wells were covered with parafilm, incubated overnight at 4°C, and tapped until dry. The antigen was then overcoated by adding 200 $\mu\text{l}$  1% BSA in 0.25 molar sodium citrate, incubating at room temperature (20-25°C) for 1 hour, and tapping the wells dry. 200 microliters of 7.5% sucrose in 0.25 molar sodium citrate was then added to each well and incubated at room temperature for 30 minutes. The resulting strips were used immediately, or dried under vacuum for 6 hours at room temperature for later use.

Assays were performed by adding 100  $\mu\text{l}$  of

20

feline serum sample (positive control, negative control, or test sera) diluted 1 to 100 in Dulbecco's PBS containing 0.1% Bovine serum albumin, 30% calf serum, and 0.05% Tween-20 (Sigma Chemical, St. Louis, MO) to a well, incubating at room temperature for 30 minutes, and tapping the well dry. The wells were washed immediately two times with Dulbecco's PBS containing 0.05% Tween-20, tapping the wells dry after the second wash.

100  $\mu$ l of a solution containing antibodies to feline immunoglobulin was then added. These antibodies were conjugated to an indicator enzyme (e.g., alkaline phosphatase) and then dissolved in a solution of 50% fetal calf serum, 0.05% Tween-20 in 0.05M Tris-HCl, pH 7.6. The wells were incubated at room temperature for 30 minutes, tapped dry, and then washed two times with Dulbecco's PBS containing 0.05% Tween-20.

A solution containing 0.1% 3,3',5,5'-Tetramethylbenzidine in 40% Glycerol and 60% methanol was mixed with an equal volume of a solution containing 22.82 grams dibasic potassium phosphate, 19.2 grams citric acid and 1.34 milliliters 30% hydrogen peroxide solution per liter. One hundred microliters of this solution was added to each well, and then incubated at room temperature for 15 minutes. At the end of the incubation period, 100  $\mu$ l of 0.25% hydrofluoric acid was added to each well. The optical density at 650 nanometer of the solution in each well was then determined with a microtiter plate reader. An immune response to p10, p15 and p26 was detectable either following experimental infection of a cat with FIV, or in feline sera possessing antibodies to FIV.

#### FIV Nucleic Acid

FIV nucleic acid is useful for production of large amounts of FIV polypeptides, or fragments thereof,

21

and also for detection of homologous nucleic acid in vivo, using standard techniques. There follows an example of cloning of FIV viral DNA. The specific FIV strain chosen is not meant to be limiting in this invention and those skilled in the art will recognize that equivalent nucleic acid may be isolated by use of the cloned sequences which are provided as specific deposits, or by techniques similar to those described in this example.

A Crandall feline kidney cell line productively infected with FIV strain 2428 (Pentaluma isolate) was used as a source of unintegrated viral DNA. The unintegrated viral DNA was prepared by Hirt extraction and CsCl-ethidium bromide centrifugation to resolve linear and supercoiled viral DNA. (Hirt, 26 J Mol. Biol. 365, 1967; Canaani et al., 282 Nature 378, 1979).

The supercoiled viral DNA was used to construct libraries which contain overlapping viral DNA sequences. The procedures used to construct these libraries were similar to those described by Maniatis et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Lab, Cold Spring Harbor, N.Y.) and Glover, DNA Cloning, Vol. 1, A Practical Approach, IRL Press, Washington, DC) and are familiar to those of ordinary skill in the art.

Two viral DNA libraries were generated by cleavage of supercoiled viral DNA by one of two restriction endonucleases. Partial cleavage by the restriction endonuclease RsaI, which recognizes the DNA sequence 5'GTAC3', or cleavage by the restriction endonuclease HaeIII, which recognizes the DNA sequence 5'GGCC3', of the supercoiled viral DNA generates two sets of blunt-ended DNA molecules whose sequences overlap. The blunt-ended DNA molecules were then

22

5 treated with EcoRI methylase, according to the  
manufacturer's directions, to modify the 3' adenine  
residue of the EcoRI recognition sequence 5'-GAATCC-3'.  
Methylation at this site inhibits the cleavage of  
10 treated DNA by the restriction endonuclease EcoRI. The  
methylated DNA molecules were then ligated to linker DNA  
molecules which contained a cleavage site for the  
restriction endonuclease EcoRI. The linker containing  
15 DNA molecules were then treated with the restriction  
endonuclease EcoRI to generate molecules whose termini  
were compatible with the EcoRI cloning site in the  
recombinant DNA phage vector  $\lambda$  ZAP" (Stratagene, La  
Jolla, California). Linker fragments resulting from  
this cleavage were separated from the large DNA  
20 molecules by size separation on a quickspin column  
(Boehringer, Mannheim, Indianapolis, IN). The DNA  
molecules were then ligated into the EcoRI cleaved  $\lambda$   
ZAP vector using T4 DNA ligase (New England Biolabs,  
Beverly, MA). Ligated DNA molecules were then packaged  
25 into phage using Gigapack gold (Stratagene, La Jolla,  
California). Viable phage from the packaging reaction  
were then amplified by infecting BB4 cells (Stratagene)  
and harvesting plate lysates of those infected cells in  
order to obtain a stock of recombinant  $\lambda$ ZAP clones.

30 Because the insert DNA of the recombinant  
 $\lambda$ ZAP clones contain host cellular DNA as well as FIV  
proviral DNA sequences, it was necessary to screen each  
library with an FIV DNA probe that contains a readily  
detectable label. Such a probe was made from RNA  
isolated from FIV. A radioactive complementary DNA was  
synthesized from total viral RNA essentially as  
described by Maniatis et al. 1982, supra except that  
selection of poly A-containing RNA was not performed,  
and methylmercuric hydroxide was omitted from the

23

protocol.

The bacteriophage libraries were plated at a density of 10,000 bacteriophage per 150 mm dish. They were then screened by hybridization of the radioactively labeled probe to phage DNA which was immobilized on nitrocellulose filters (Maniatis, et al., 1982 supra). Each hybridizing bacteriophage plaque was then picked, replated, and hybridized as described, until a single well was isolated which contained a  $\lambda$ ZAP recombinant clone. XL-1-Blue cells (Stratagene) were then infected with recombinant  $\lambda$ ZAP phage, and plasmids containing the insert DNA were obtained following superinfection with R408 helper phage according to the manufacturer's directions (Stratagene, La Jolla, California). This procedure also provides both recombinant plasmids (which can be isolated from the cell) and single stranded phage stock which can be isolated from the medium for DNA sequence analysis.

The above recombinant plasmids were analyzed for inserts by preparing plasmid DNAs from overnight culture of bacteria replicating these plasmids as follows. One and one half ml. of an overnight culture was placed in a microcentrifuge tube and spun for four minutes at 4000xg. The supernatant was removed and the tube respun for four minutes at 4000xg. The supernatant was removed and the tube respun for a few seconds, and residual liquid removed carefully with a pasteur pipet. The bacterial pellet was then thoroughly resuspended in 200 microliters of a solution containing 8% sucrose, 50 mM EDTA, 5% Triton X-100 and 50 mM Tris/HCl, pH 8.05. 20 microliters of a lysozyme solution at a concentration of 10 milligrams lysozyme per milliliter in 10 millimolar Tris/HCl, pH 8 and one millimolar EDTA was then added, mixed, and the mixture was incubated at 4°C

24

for 15 minutes. The solution containing bacteria was then placed in a boiling water bath for 90 seconds. The mixture was chilled on ice, and spun in a microfuge in the cold for 10 minutes at 11,000 xg. The pellet was carefully removed with a glass pipet. Ice cold isopropanol (200 microliters) was then added, the solution thoroughly mixed, and incubated at -20°C for 5 minutes. The chilled solution was centrifuged at -20°C at 11,000 xg for 10 minutes to pellet the plasmid DNA. The supernatant was carefully removed and the pelleted DNA briefly air dried. The DNA pellet was then dissolved in 100 microliters of sterile double distilled water. Plasmid DNAs thus isolated were analyzed for inserts by restriction endonuclease cleavage and electrophoresis in 0.8% agarose gels. (Maniatis et al., 1982 supra).

Standard dideoxy sequence analysis was performed on the recombinant DNA containing clones. Single stranded phage were isolated from the media used to propagate cells containing the bluescript plasmid using the method generally described in the M13 dideoxy sequencing manual published by Bethesda Research Laboratories (Gaithersburg, Maryland). A number of clones were sequenced and analyzed by this method. Sequence information for clones termed 10CX, 2BY, and R5X is presented in Figure 5a, b, and c along with the putative translated amino acid sequence for each clone. These amino acid sequences show homology with the amino acid sequence of the envelope gene of equine infectious anemia virus, a lentivirus, immunologically closely related to FIV.

Nucleic acid probes derived from the 2BY DNA sequence hybridize to DNA isolated from FIV infected but not uninfected cells. These probes can be used to

25

isolate other FIV genes from other strains and can be expressed by standard procedures to provide the purified polypeptides described above.

Deposit

5 Strains 10CX, 2B4 and R5X have been deposited with the ATCC and assigned numbers 67937, 67938, and 67939, respectively.

10 Applicants' and their assignees acknowledge their responsibility to replace these cultures should they die before the end of the term of a patent issued hereon, 5 years after the last request for a culture, or 30 years, whichever is the longer, and its responsibility to notify the depository of the issuance of such a patent, at which time the deposits will be  
15 made irrevocably available to the public. Until that time the deposits will be made available to the Commissioner of Patents under the terms of 37 CFR Section 1-14 and 35 USC Section 112.

20 Other embodiments are within the following claims.

26

Claims

1. A purified polypeptide comprising an epitope of an antigenic polypeptide of FIV.

5 2. The purified polypeptide of claim 1, said peptide comprising an epitope of a gag or env polypeptide of FIV.

10 3. The purified polypeptide of claim 2 wherein said polypeptide comprises a polypeptide having at least 75% homology to said gag or env polypeptide.

15 4. The purified polypeptide of claim 3 wherein said polypeptide comprises a gag or env polypeptide of FIV.

5. The purified polypeptide of claim 2, 3, or 4 wherein said polypeptide is p10, p15, or p26.

20 6. The purified polypeptide of claim 2, 3 or 4 wherein said polypeptide is gp40, gp100, or gp130.

25 7. A method for detecting antibody to FIV comprising providing purified polypeptide comprising an epitope of an antigenic polypeptide of FIV, contacting said purified polypeptide with a sample comprising said antibody, and detecting the presence of a complex formed between said polypeptide and said antibody.

30 8. A purified nucleic acid comprising a 50 nucleotide sequence having at least 90% homology with a 50 nucleotide sequence naturally occurring in an FIV particle.

27

9. The nucleic acid of claim 8, said nucleic acid encoding a polypeptide comprising an epitope of an antigenic polypeptide of FIV.

5 10. The nucleic acid of claim 9, said polypeptide comprising an epitope of a gag or env polypeptide of FIV.

10 11. The nucleic acid of claim 8 carried in an expression vector.

15 12. A method for inducing immunity to FIV-caused disease symptoms in a cat, comprising the step of inoculating the cat with a polypeptide of claim 1.

20 13. A purified polypeptide comprising ten or more contiguous amino acids taken from the sequence V-Q-S-R-G-S-G-P-V-C-F-N-C-K-K-P-G-H-L-A-R-Q-S-H or P-I-Q-T-V-N-G-V-P-Q-Y-V-A-L-D-P-K-M-V-S or S-V-Q-S-R-G-Q-G-P-V-A-F-N.

**THIS PAGE BLANK (USPTO)**

Fig. 5c

translation of R5XCXL1 over region 1-172.

10 20 30 40 50  
 \* \* \* \* \*  
 GCG ACC AAC TCC CAA TCG TGC GAA AAT GTA TTC TCG AGT NAC CTG CCA AAT  
 CGC TGG TTG AGG GTT AGC ACG CTT TTA CAT AAG AGC TCA NTG GAC GGT TTA  
 Ala Thr Asn Ser Gln Ser Cys Glu Asn Val Phe Ser Ser Xxx Leu Pro Asn)  
 ---a---a---a---a---a---AUTOTRANSLATION OF R5XCXL1\_a---a---a---a---a---

	EO				70				80				90				100			
	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*		
GGA	CAC	AAC	ACA	GTT	TGG	GAA	CAG	GTG	GTC	TTT	CCT	CTN	AGT	ATT	TTT	TTG				
CCT	GTG	TTG	TGT	CAA	ACC	CTT	GTC	CAC	CAG	AAA	GGA	GAN	TCA	TAA	AAA	ACC				
Gly	His	Asn	Thr	Val	Trp	Glu	Gln	Val	Val	Phe	Pro	Leu	Ser	Ile	Phe	Trp)				
---	a	---	a	---	a	---	a	---	a	---	a	---	a	---	a	---	a			
AUTOTRANS LATION OF R5XCXL1_a_																				

110					120					130					140					150				
GAT	CTA	TTT	NTN	AGA	GTG	AGA	AAT	TGT	GTG	TTG	ACG	TCC	CTT	TTT	CCT	TTT								
CTA	GAT	AAA	NAN	TCT	CAC	TCT	TTA	ACA	CAC	AAC	TGC	AGG	GAA	AAA	GGG	AAA								
Asp	Leu	Phe	Xxx	Arg	Val	Arg	Asn	Cys	Val	Leu	Thr	Ser	Leu	Phe	Pro	Phe								
AUTOTRANSLATION OF R5XCXL1																								

```

      160              170
      *              *
AGG GAT CTG GTC ATA T T C T
TCC CTA GAC CAG TAT AAG A
Arg Asp Leu Val Ile Phe)
___AUTOTRANSLATION OF__a_)

```




FIG. 1






FIG. 2

SDS-PAGE Electrophoresis  
15% Bis-Acrylamide gel.  
70 Volts - overnight

Silver STAINED w/ BIORAD silver STAINING KIT # 161-



CHANNEL A INJECT 08/01/88 17 20 STOPPED TO EIM 4 2



IBI Pustell Sequence Analysis Programs  
 Ver 2.02 Copyright J.Pustell 1987-1989  
 Mon Apr 3, 1989 - 3:19 PM  
 Translation Analysis of 10CXXL3

Fig 5a

translation of 10CXXL3 over region 3-202.

```

      10      20      30      40      50
      *      *      *      *      *
AA GAT GAA CAA GGA GTA GCA AAA AGC AAA GTC AAA GAA CTG CTA ACG TAT GTT
TT CTA CTT GTT CCT CAT CGT TTT TCG TTT CAG TTT CTT GAC GAT TGC ATA CAA
   Asp Glu Gln Gly Val Ala Lys Ser Lys Val Lys Glu Leu Leu Thr Tyr Val)
   _a_ _a_ _a_ _a_ AUTOTRANSlation OF 10CXXL3 _a_ _a_ _a_ _a_ _a_ _a_ _a_
   _b_ _b_ _b10_ _b_ _b_ _b_20b_ _b_10CXCOn_ _b_ _b_ _b40_ _b_ _b_ _b50b_

```

```

      60      70      80      90     100
      *      *      *      *      *
TTG TTG ATA CAA CTC TCA TAA AAA TAT AAA ATG AAC ACA TCG GCA AAA ATC
AAC AAC TAT GTT GAG AGT ATT TTT ATA TTT TAC TTG TGT AGC CGT TTT TAG
Leu Leu Ile Gln Leu Ser End Lys Tyr Lys Met Asn Thr Ser Ala Lys Ile)
   _a_ _a_ _a_ _a_ AUTOTRANSlation OF 10CXXL3 _a_ _a_ _a_ _a_ _a_ _a_ _a_
   _b_ _b60_ _b_ _b_ _b70_ _b_ _b_10CXCOn_ _b_ _b_ _b90_ _b_ _b_ _b100_ _b_

```

```

      110      120      130      140      150
      *      *      *      *      *
TAT CTA ACT CAT AAG TTA ACA AGG AAA CCA GTG TTG CTA CCG ATT CTA AGA
ATA GAT TGA GTA TTC AAT TGT TCC TTT GGT CAC AAC GAT GGC TAA GAT TCT
Tyr Leu Thr His Lys Leu Thr Arg Lys Pro Val Leu Leu Pro Ile Leu Arg)
   _a_ _a_ _a_ _a_ AUTOTRANSlation OF 10CXXL3 _a_ _a_ _a_ _a_ _a_ _a_ _a_
   _b110b_ _b_ _b_ _b120_ _b_ _b_10CXCOn_ _b_ _b140b_ _b_ _b_ _b150_ _b_

```

```

      160      170      180      190      200
      *      *      *      *      *
ATT CCC CTG GCT GCT CGG GAG CGC GCC CNC GGA GGG GAA TTC AGT GC
TAA GGG GAC CGA CGA GCC CTC GCG CGG GNG CCT CCC CTT AAG TCA CG
Ile Pro Leu Ala Ala Arg Glu Arg Ala Xxx Gly Gly Glu Phe Ser Ala)
   _a_ _a_ _a_ _a_ AUTOTRANSlation OF 10CXXL3 _a_ _a_ _a_ _a_ _a_ _a_ _a_
   _b160_ _b_ _b_ _b170b_ _b_ _b_10CXCOn_ _b_ _b_ _b190_ _b_ _b_ _b200b_

```

-6/-

181 Pustell Sequence Analysis Programs  
 Ver 2.02 Copyright J. Pustell 1987-1989  
 Mon Apr 3, 1989 - 3:25 PM  
 Translation Analysis of 2BYCXL2

14.36

lation of 2BYCXL2 over region 2-163.

```

      10      20      30      40      50
      *      *      *      *      *
G GAT CCT GAC CGG CAC CGT CCC TTG TGC CCT CAA CTN AGC CTG TCG GGG AGA
C CTA GGA CTG GCC GTG GCA GGG AAC ACG GGA GTT GAN TCG GAC AGC CCC TCT
  Asp Pro Asp Arg His Arg Pro Leu Cys Pro Gln Leu Ser Leu Ser Gly Arg)
  a a a a a AUTOTRANSlation OF 2BYCXL2 a a a a a
( b160b b b 150 b b 1 2BYCON b130b b b 120 b b

```

```

      60      70      80      90     100
      *      *      *      *      *
CCA CTG CCC TGC TGT GGG TTC GGC GCC TGG AAC TTC CTG GGA CCT AAC CCT
GGT GAC GGG ACG ACA CCC AAG CCG CGG ACC TTG AAG GAC CCT GGA TTG GGA
Pro Leu Pro Cys Cys Gly Phe Gly Ala Trp Asn Phe Leu Gly Pro Asn Pro)
  a a a a a AUTOTRANSlation OF 2BYCXL2 a a a a a
(110 b b b100b b b 9 2BYCON b80 b b b 70b b b

```

```

     110     120     130     140     150
      *      *      *      *      *
AAC CCT AAG CCC TAC CCC GAA CCG GAC CCT CCC CTG AAA NCT AAC GCC TGC
TIG GGA TTC GGG ATG GGG CTT GGC CTG GGA GGG GAC TTT NGA TTG CGG ACG
Asn Pro Lys Pro Tyr Pro Glu Pro Asp Pro Pro Leu Lys Xxx Asn Ala Cys)
  a a a a a AUTOTRANSlation OF 2BYCXL2 a a a a a
(60 b b b50 b b b 40b 2BYCON 30 b b b30 b b b 10

```


```

    160
      *
CTC GAT CCC
GAG CTA GGG
Leu Asp Pro)
  a
( b b

```

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US90/02338

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5): C07K 13/00, 9/00; C12Q 1/00; A61K 39/00; C07H 15/12 U.S.Cl.: 530/350,395; 435/7; 424/88,89; 536/27		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
U.S.	530/350,395; 435/7; 424/88,89, 536/27	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>*</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	Science, Volume 235, published 13 February 1987. N. Pedersen, et al. "Isolation of a T-Lymphotropic virus from domestic cats with an immunodeficiency-like syndrome" pp. 790-793. see entire article.	1-13
X,P Y,P	Proc. Natl. Acad. Sci. USA, Volume 86, published October 1989. R. Olmsted, et al. "Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses" pp. 8088-8092. see entire article.	8-11 1-7, 12-13
X,P Y,P	Proc. Natl. Acad. Sci. USA, Volume 86, published August 1989. R. Talbott et al. "Nucleotide sequence 1-7, 12-13 and genomic organization of feline immunodeficiency virus" pp. 5743-5747. see entire article.	8-11 1-7, 12-13
Y	Science, Volume 234, published 12 December 1986. S. Putney, et al. "HTLV-III/LAV-neutralizing antibodies to an E.coli-produced fragment of the virus envelope" pp. 1392-1395. see entire article.	12
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>*</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
16 August 1990		28 SEP 1990
International Searching Authority		Signature of Authorized Officer
ISA/US		 Richard A. Schwartz

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y

US, A, 4,708,818 (MONTAGNIER) 24 November 1987  
see entire document.

7

V ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers \_\_\_\_\_ because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>11</sup>, specifically:
  
3. ☐ Claim numbers \_\_\_\_\_, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
  
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
  
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remarks on Protest

- ☐ The additional search fees were accompanied by applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**

17. 5,409,698, Apr. 25, 1995, Liposome immunoadjuvants containing IL-2; Peter M. Anderson, et al., 424/85.2, 283.1, 423, 450, 812 [IMAGE AVAILABLE]
18. 5,405,939, Apr. 11, 1995, 2',5'-phosphorothioate oligoadenylates and their covalent conjugates with polylysine; Robert J. Suhadolnik, et al., 530/322; 525/54.2; 530/395; 536/25.2 [IMAGE AVAILABLE]
19. 5,403,586, Apr. 4, 1995, LHRH-TraTp fusion proteins; Gregory J. Russell-Jones, et al., 424/192.1, 198.1, 811; 435/69.3, 69.4, 69.7, 252.3, 320.1; 536/23.4; 930/130 [IMAGE AVAILABLE]
20. 5,403,484, Apr. 4, 1995, Viruses expressing chimeric binding proteins; Robert C. Ladner, et al., 435/235.1, 69.7, 172.3, 252.3, 320.1; 530/350; 536/23.4 [IMAGE AVAILABLE]
21. 5,399,485, Mar. 21, 1995, Methods and compositions for diagnosing **\*\*cat\*\*** scratch disease and bacillary angiomatosis caused by *Rochalimaea henselae*; Russell L. Regnery, et al., 435/7.32, 6; 436/811; 530/387.1, 388.4, 389.5, 391.1, 391.3 [IMAGE AVAILABLE]
22. 5,387,676, Feb. 7, 1995, MN gene and protein; Jan Zavada, et al., 536/23.5; 435/69.1, 240.2, 240.4, 252.3, 254.11, 254.2, 320.1; 536/24.31 [IMAGE AVAILABLE]
23. 5,386,030, Jan. 31, 1995, Antiviral (phosphonomethoxy)methoxy purine/pyrimidine derivatives; Choung U. Kim, et al., 544/243, 244; 558/87, 177, 189 [IMAGE AVAILABLE]
24. 5,386,013, Jan. 31, 1995, Tumor necrosis factor-induced protein TSG-6; Tae H. Lee, et al., 530/350; 435/69.1; 530/351 [IMAGE AVAILABLE]
25. 5,384,122, Jan. 24, 1995, Herpesvirus particles and **\*\*vaccine\*\***; Charles Cunningham, et al., 424/231.1; 435/172.1, 235.1; 530/350 [IMAGE AVAILABLE]
26. 5,380,830, Jan. 10, 1995, Molecular clones of bovine immunodeficiency-like virus; Matthew A. Gonda, 536/23.1; 435/235.1, 236, 320.1; 536/23.72; 935/6, 9, 19, 32 [IMAGE AVAILABLE]
27. 5,376,369, Dec. 27, 1994, **\*\*Vaccine\*\*** adjuvant; Anthony C. Allison, et al., 424/278.1, 279.1, 283.1; 436/543; 514/8, 885; 530/322, 806, 815 [IMAGE AVAILABLE]
28. 5,374,548, Dec. 20, 1994, Methods and compositions for the attachment of proteins to liposomes using a glycopospholipid anchor; Ingrid W. Caras, 424/450; 435/69.7; 436/829 [IMAGE AVAILABLE]
29. 5,371,017, Dec. 6, 1994, Hepatitis C virus protease; Michael Houghton, et al., 435/320.1, 69.1, 69.7; 536/23.2, 23.4, 23.72 [IMAGE AVAILABLE]
30. 5,354,866, Oct. 11, 1994, Retroviral protease inhibiting compounds; Dale J. Kempf, et al., 546/265 [IMAGE AVAILABLE]
31. 5,354,674, Oct. 11, 1994, Method of gene transfer using retrotransposons; Clague P. Hodgson, 435/172.3, 69.1, 172.1, 172.2, 235.1, 240.2, 320.1 [IMAGE AVAILABLE]
32. 5,352,665, Oct. 4, 1994, Method of treating disease caused by the infection of virus; Akira Awaya, et al., 514/15; 530/328 [IMAGE AVAILABLE]
33. 5,352,449, Oct. 4, 1994, **\*\*Vaccine\*\*** comprising recombinant **\*\*feline\*\*** leukemia antigen and saponin adjuvant; Gerald A. Beltz, et al., 424/187.1, 207.1, 278.1, 819; 514/8, 12 [IMAGE AVAILABLE]
34. 5,350,835, Sep. 27, 1994, Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of **\*\*aids\*\***; Richard B. Gaynor, et al., 530/358; 435/974; 530/350; 930/221 [IMAGE AVAILABLE]
35. 5,350,683, Sep. 27, 1994, DNA encoding type II interleukin-1 receptors; John E. Sims, et al., 435/69.1, 252.3, 320.1; 530/350; 536/23.5 [IMAGE AVAILABLE]
36. 5,350,672, Sep. 27, 1994, Specific DNA primers and method to use

**THIS PAGE BLANK (USPTO)**

same detect Eperythrozoon suis; Richard D. Oberst, et al., 435/6, 252.1; 536/24.3, 24.32 [IMAGE AVAILABLE]

37. 5,350,671, Sep. 27, 1994, HCV immunoassays employing C domain antigens; Michael Houghton, et al., 435/5, 6, 975; 436/512, 518; 530/300, 326, 327, 328, 812, 826; 930/220, 223 [IMAGE AVAILABLE]

38. 5,348,887, Sep. 20, 1994, Vectors and DNAs for expression of a human adenocarcinoma antigen; Thomas F. Bumol, et al., 435/320.1, 69.3, 172.3, 240.1, 252.3, 252.33; 536/23.5 [IMAGE AVAILABLE]

39. 5,328,987, Jul. 12, 1994, IgA Fc receptors; Charles R. Maliszewski, 530/350; 435/69.1 [IMAGE AVAILABLE]

40. 5,324,643, Jun. 28, 1994, Method of conferring resistance to retroviral infection; Wilson Greatbatch, et al., 435/91.32, 91.1, 91.3, 172.3, 240.1, 240.2; 536/23.1; 935/3, 6, 34, 70 [IMAGE AVAILABLE]

41. 5,321,124, Jun. 14, 1994, Art (rev) protein of human T-cell leukemia virus; William A. Haseltine, et al., 530/350; 424/188.1, 208.1; 435/5, 235.1; 530/395; 930/220, 221 [IMAGE AVAILABLE]

42. 5,319,071, Jun. 7, 1994, Soluble interleukin-1 receptors; Steven K. Dower, et al., 530/350; 424/85.2; 530/351, 395, 402; 930/141 [IMAGE AVAILABLE]

43. 5,316,931, May 31, 1994, Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes; Jon Donson, et al., 435/172.3, 69.1, 70.1, 320.1; 536/23.72, 24.1; 800/205; 935/25, 57, 64, 67 [IMAGE AVAILABLE]

44. 5,310,663, May 10, 1994, Affinity peptides; Heinz Dobeli, et al., 435/69.7, 240.1, 320.1; 530/413; 536/23.1 [IMAGE AVAILABLE]

45. 5,308,838, May 3, 1994, Uses of aloe products; Bill H. McAnalley, et al., 424/278.1; 514/54, 885 [IMAGE AVAILABLE]

46. 5,306,614, Apr. 26, 1994, Methods and kits for diagnosing human immunodeficiency virus type 2(\*\*HIV\*\*-2); Marc Alizon, et al., 435/5, 7.1, 7.92, 7.93, 7.94, 7.95, 974; 530/300, 324, 325, 326, 350 [IMAGE AVAILABLE]

47. 5,304,637, Apr. 19, 1994, Expression and purification of human interleukin-3 and muteins thereof; Lambertus C. J. Dorssers, et al., 530/351; 435/69.5, 69.52; 530/412, 413, 415, 417, 418, 419, 420; 930/141 [IMAGE AVAILABLE]

48. 5,302,517, Apr. 12, 1994, Method of controlling the expression of a gene in a cell culture, cell culture vector used in the method and method of making the vector; Solon L. Rhode, III, 435/69.1, 172.3, 240.2; 935/11, 33, 34 [IMAGE AVAILABLE]

49. 5,298,422, Mar. 29, 1994, Myogenic vector systems; Robert J. Schwartz, et al., 435/320.1, 69.1, 69.4, 172.3 [IMAGE AVAILABLE]

50. 5,288,639, Feb. 22, 1994, Fungal stress proteins; James P. Burnie, et al., 435/320.1, 921, 922, 924; 530/300, 327, 328, 329, 330, 350, 371, 806, 823; 536/23.74; 935/9, 11, 12 [IMAGE AVAILABLE]

51. 5,286,852, Feb. 15, 1994, Antibodies specific towards \*\*HIV\*\*-1 gp 48; Kurt B. Osther, 530/388.35; 435/240.27; 530/387.1, 389.4 [IMAGE AVAILABLE]

52. 5,284,933, Feb. 8, 1994, Affinity peptides; Heinz Dobeli, et al., 530/350; 435/69.7; 530/324, 409, 413 [IMAGE AVAILABLE]

53. 5,281,520, Jan. 25, 1994, Method for producing acyloxyacyl hydrolase; Patrick J. O'Hara, et al., 435/69.1, 172.3, 197, 252.3, 320.1; 536/23.1, 23.2; 935/9, 14, 28, 32, 68, 70 [IMAGE AVAILABLE]

54. 5,275,813, Jan. 4, 1994, Methods and compositions for \*\*vaccinating\*\* against \*\*feline\*\* immunodeficiency virus; Janet K. Yamamoto, et al., 424/208.1, 819 [IMAGE AVAILABLE]

55. 5,270,167, Dec. 14, 1993, Methods of identification employing antibody profiles; Ann-Michele Francoeur, 435/7.21, 7.23, 7.24, 7.95;

**THIS PAGE BLANK (USPTO)**